Loading clinical trials...
Loading clinical trials...
Evaluation of PSA Blood Levels in Men on Active Surveillance and Men With Benign Prostatic Hyperplasia Prior to and After Digital Rectal Examination
Patients with know prostate cancer (PCa) under active surveillance and aged matched controls without evidence of PCa will have a PSA blood test prior to and following standardized digital rectal examination
Patients with know prostate cancer (PCa) under active surveillance (Gleason 6, PSA \< 10 ng/ml) and aged matched controls without evidence of PCa will have a PSA blood test prior to and following standardized digital rectal examination. The change of PSA will be evaluated.
Age
18 - 99 years
Sex
MALE
Healthy Volunteers
No
Kaplan Medical Center
Rehovot, Israel
Start Date
May 1, 2016
Primary Completion Date
May 1, 2017
Completion Date
May 1, 2017
Last Updated
April 21, 2016
60
ESTIMATED participants
Blood test (PSA)
OTHER
Lead Sponsor
Kaplan Medical Center
NCT05691465
NCT04550494
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions